National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
302 articles with National Institute of Allergy & Infectious Diseases (NIAID)
NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced an agreement with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, to develop NeoImmuneTech's main asset NT-I7, for the treatment of Acute Radiation Syndrome.
Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae
Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health.
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 MillionNIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis
AN2 Therapeutics, Inc. today announced the award of a contract valued up to $17.8 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of epetraborole for acute systemic melioidosis.
NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421
United BioPharma announced that the U.S. Food and Drug Administration has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases of NIH.
After more than two decades of attempts to develop a universal influenza vaccine, the global COVID-19 pandemic intensified the need for a broader vaccine for both illnesses.
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex
Fortress Biotech, Inc. today announced that Triplex, a cytomegalovirus (“CMV”) vaccine being developed by its subsidiary Helocyte, Inc. (“Helocyte”), received a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (“NIAID/NIH”) that could provide over $20 million in non-dilutive funding.
Experts from U.S. health regulatory agencies have announced plans to conduct a clinical trial to assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral for monkeypox.
Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.
NIH/NIAID Locks ACTIV-5/BET-B Database
Humanigen, Inc. confirms that notice was received from the National Institute of Allergy and Infectious Diseases that they have completed database lock for the Big Effect Trial of lenzilumab being conducted as part of the National Institutes of Health public-private partnership Accelerating COVID-19 Therapeutic Interventions and Vaccines.
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
Cocrystal Pharma, Inc. announces a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases for exploratory preclinical studies to evaluate the potential of Cocrystal’s 3CL protease inhibitors for the treatment of COVID-19.
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
New studies suggest that the virus may aggravate childhood asthma after infection. For that and more COVID-19 news, continue reading.
There are very few ongoing clinical trials on treatments for Long COVID and there has been what appears to be a successful treatment using Pfizer’s Paxlovid. Read on for more details.
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
COVID-19 has killed more than six million people worldwide and almost one million in the U.S. And the pandemic isn’t over yet. Read on for that and more updates about COVID-19.
Norman E. “Ned” Sharpless will step down from his role as director of the National Cancer Institute (NCI) at the end of this month, after serving in the role since 2017.
Novavax announced today that its protein-based Covid-19 vaccine, NVX-CoV2373, is included in two new clinical trials that will evaluate the vaccine as a potential Covid booster.
ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Develop Well-Characterized Challenge Material of BSL-3 and BSL-4 Viruses
ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a task order contract, with a ceiling value of $1.9 million, by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop well-characterized challenge material for therapeutic development.
Leidos awarded NIAID contract to support biomedical research
Leidos, a FORTUNE® 500 science and technology leader, was recently awarded a new prime contract to provide biomedical preclinical and development capabilities to support the National Institute of Allergy and Infectious Diseases.
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
SAB Biotherapeutics announced an update to the design of the ongoing Phase 3 ACTIV-2 trial evaluating the clinical efficacy and safety of SAB-185 for the treatment of participants with mild-moderate COVID infections at higher risk for progression to hospitalization.